generation run 2026-05-09
66 min completedmodel pipeline-v5plan not recordedrun/7ce0468c…Selection
Verification
- record
- seen / partial
- working
The model's own caveats
- sparse_evidence
- safety_data_unverified
Reproduce
- inputs
- 22 source keys (listed under Sources)
- plan
- not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
- model
- pipeline-v5
- streams
- none — agent transcripts are persisted from 2026-09 onward
16 searches — query, source, results, what was kept and why
| # | source | query | seen | kept | rationale |
|---|---|---|---|---|---|
| 1 | PubMed | designer benzodiazepine GABA binding affinity NPS new psychoactive substances | 1 | 1 | Directly relevant to GABA-A binding pharmacodynamics including nifoxipam |
| 2 | OpenAlex | nifoxipam designer benzodiazepine | 10 | 6 | High-citation reviews and analyses that contextualize nifoxipam pharmacology and harms |
| 3 | ClinicalTrials.gov · absence | nifoxipam benzodiazepine | 0 | 0 | No results found |
| 4 | PubMed | STRIDA project designer benzodiazepine intoxication NPS Sweden | 8 | 2 | STRIDA data contains confirmed nifoxipam intoxication cases |
| 5 | WebSearch + UK legislation | nifoxipam legal status UK USA scheduling controlled substance | 10 | 2 | Primary legal status sources |
| 6 | PubMed | nifoxipam pharmacology toxicology | 6 | 1 | Duplicate coverage confirmed |
| 7 | PubChem | nifoxipam | 1 | 1 | Primary chemical identity source |
| 8 | PubMed | nifoxipam benzodiazepine | 15 | 7 | All directly relevant to nifoxipam pharmacology, metabolism, and clinical toxicology |
| 9 | ClinicalTrials.gov · absence | nifoxipam | 0 | 0 | No results |
| 10 | Wikipedia | Nifoxipam Wikipedia | 1 | 0 | Inaccessible; used other sources |
| 11 | UK legislation + WebSearch | nifoxipam UK Misuse of Drugs 2017 Schedule 1 Class C | 1 | 2 | Confirms UK scheduling as Class C, Schedule 1 |
| 12 | PubMed Central | PMC5214877 full text nifoxipam | 1 | 4 | Primary source for nifoxipam history, doses, effects, legal status |
| 13 | Crossref DOI verification | DOI verification for key nifoxipam papers | 3 | 3 | DOI verification confirmed |
| 14 | WebSearch | nifoxipam EMCDDA EUDA scheduling Australia Canada Finland | 10 | 3 | Legal status across jurisdictions |
| 15 | OpenAlex | nifoxipam fonazepam flunitrazepam metabolite drug market forensic toxicology | 6 | 2 | DFSA risk and parent compound GABA-A pharmacology relevant to nifoxipam |
| 16 | WebSearch | nifoxipam logP solubility melting point physical properties | 10 | 1 | Physical property data |
81 claims by section — every cited sentence, checked against its source
safety21 · 13 ok
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Respiratory depression is the primary life-threatening risk, occurring at high doses or — more commonly — in combination with other CNS depressantssupported
illicit BZDs combined with opiates lead to respiratory depression and death. dta.2211
Respiratory depression is the primary life-threatening risk, occurring at high doses or — more commonly — in combination with other CNS depressantssupported
High doses or combination with other sedatives causes respiratory depression, coma, death. jcph.1922
Clinical intoxication data from the Swedish STRIDA project (five confirmed nifoxipam cases) showed CNS depression as the most prominent finding; all cases involved polysubstance usepartially supported
Nifoxipam detected in 5 of 217 NPS BZD intoxication cases in Sweden 2012-2016. CNS depression most prominent. 15563650.2018.1506130
Across the full US NPDS designer benzodiazepine dataset (2014–2017), 36% of single-agent exposures required hospital admission, 22% required ICU admission, and 3% required intubation.partially supported
234 single agent designer BZD exposures in USA 2014-2017; 22% ICU admission. 15563650.2018.1510502
This combination is the primary mechanism of benzodiazepine-related death.{{/Warning}}supported
illicit BZDs combined with opiates lead to respiratory depression and death. dta.2211
Claim in safety — not_supportednot supportedworking →
Designer benzodiazepines have been identified as emerging DFSA agents in forensic literature: they are active at low doses (0.5–1 mg oral), produce amnesia and disinhibition, can be dissolved in beverages, and are difficult to detect on standard immunoassays unless the laboratory explicitly tests for their metabolites.supported
DBZDs active at low doses, fast onset, easily administered orally — ideal DFSA candidates. bkac017
Designer benzodiazepines have been identified as emerging DFSA agents in forensic literature: they are active at low doses (0.5–1 mg oral), produce amnesia and disinhibition, can be dissolved in beverages, and are difficult to detect on standard immunoassays unless the laboratory explicitly tests for their metabolites.supported
DFC cases 2019-2023; designer BZDs flagged for inclusion in DFC analytical scopes; sedating BZDs prevalent. 1556-4029.70151
Claim in safety — inconclusiveinconclusiveworking →
{{Emergency}}Flumazenil, the competitive benzodiazepine antagonist, effectively reverses nifoxipam-induced sedation — confirmed in STRIDA clinical casessupported
Nifoxipam detected in 5 of 217 NPS BZD intoxication cases in Sweden 2012-2016. CNS depression most prominent. Flumazenil treatment effective. 15563650.2018.1506130
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
{{Warning}}Abrupt cessation of sustained benzodiazepine use produces a potentially life-threatening withdrawal syndrome characterized by anxiety, tremors, muscle spasticity, insomnia, tachycardia, hypertension, and generalized seizuressupported
BZD withdrawal: tremors, muscle spasticity, life-threatening seizures on abrupt cessation. 0115680266296096240408032738
Illicitly obtained benzodiazepines combined with opioids can cause respiratory arrest and death.supported
illicit BZDs combined with opiates lead to respiratory depression and death. dta.2211
Claim in safety — inconclusiveinconclusiveworking →
Flumazenil reverses nifoxipam-induced sedation (confirmed clinically) but is contraindicated when cyclic antidepressant co-ingestion is suspected due to seizure risk.partially supported
CNS depression most prominent. Flumazenil treatment effective. 15563650.2018.1506130
Severe hepatic impairment: Given that nifoxipam undergoes hepatic phase I and phase II metabolism, severe liver disease may impair clearance and prolong effects unpredictably.supported
Nifoxipam extensively metabolized; main urinary target: 7-acetaminonifoxipam; also excreted as glucuronic acid conjugate of parent. s00216-016-9439-6
Severe hepatic impairment: Given that nifoxipam undergoes hepatic phase I and phase II metabolism, severe liver disease may impair clearance and prolong effects unpredictably.supported
Glucuronide conjugates of nifoxipam only detected in pHLM, not attributable to individual UGTs, suggesting dimer complexes. dta.2463
pharmacology20 · 14 ok
7-acetaminonifoxipam — most abundant urinary metabolite; best detection targetsupported
main urinary target: 7-acetaminonifoxipam. s00216-016-9439-6
Parent compound glucuronide — significant secondary targetsupported
also excreted as glucuronic acid conjugate of parent. s00216-016-9439-6
Parent compound glucuronide — significant secondary targetsupported
Glucuronide conjugates of nifoxipam only detected in pHLM. dta.2463
Parent compound (unchanged) — detected in routine testing and acute intoxication casessupported
Nifoxipam detected in patient urine samples from routine drug testing and acute intoxication cases via LC-HRMS. j.clinms.2018.08.004
Nifoxipam displays an unusual UDP-glucuronosyltransferase (UGT) profile: glucuronide conjugates were detected only in pooled human liver microsomes (pHLM) and not when 13 individual UGT enzymes were tested separatelysupported
Glucuronide conjugates of nifoxipam only detected in pHLM, not attributable to individual UGTs, suggesting dimer complexes. dta.2463
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Flunitrazepam demonstrates greater potency and higher GABA-A receptor affinity than most standard benzodiazepinessupported
Flunitrazepam has greater potency and higher affinity for GABA-A receptor than most BZDs. jcph.1922
Nifoxipam, as the N-desmethyl-3-hydroxy metabolite, retains pharmacological activity at this site, though the magnitude of its intrinsic efficacy and receptor affinity relative to the parent compound have not been quantified.supported
Nifoxipam (3-hydroxy-desmethylflunitrazepam) are benzodiazepine derivatives and active metabolites of flunitrazepam. s11419-016-0338-5
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Nifoxipam is itself an active metabolite of flunitrazepam (the N-desmethyl-3-hydroxy derivative)supported
Nifoxipam (3-hydroxy-desmethylflunitrazepam) are benzodiazepine derivatives and active metabolites of flunitrazepam. s11419-016-0338-5
The primary metabolic pathway involves nitro-reduction of the 7-nitro group to yield 7-aminonifoxipam, followed by acetylation to 7-acetaminonifoxipam — the most abundant urinary metabolite and the recommended primary detection target for forensic and clinical drug testingsupported
Nifoxipam extensively metabolized; main urinary target: 7-acetaminonifoxipam. s00216-016-9439-6
Additional phase I metabolites identified through human liver microsome (HLM) incubation include denitro-, mono-hydroxylated, di-hydroxylated, and desmethyl variants.supported
Nifoxipam incubated with HLMs; 26 metabolites identified across 8 DBZDs including denitro-, mono- or di-hydroxylated and desmethyl forms. s00414-017-1541-6
Glucuronidation of the parent compound produces a significant urinary metabolitesupported
Glucuronide conjugates of nifoxipam only detected in pHLM, not attributable to individual UGTs, suggesting dimer complexes. dta.2463
This contrasts sharply with most other designer benzodiazepines (clonazolam, deschloroetizolam, etizolam, flubromazolam, metizolam), which are glucuronidated exclusively by UGT1A4supported
Most DBZs glucuronidated by UGT1A4. dta.2463
Hair testing — validated LC-MS/MS methods exist for nifoxipam detection in hairsupported
Validated LC-MS/MS hair method for 17 designer BZDs including nifoxipam; LOQ 5-25 pg/mg. bkac044
Standard immunoassay benzodiazepine screens show high cross-reactivity with nifoxipam, though confirmatory LC-MS/MS or LC-HRMS is required for definitive identification.supported
Nifoxipam showed high cross-reactivity in standard immunoassay BZD screening. KIMS II and CEDIA showed highest reactivity. dta.2003
summary8 · 4 ok
Dependence liability is inferred from flunitrazepam and class-level benzodiazepine data: physical and psychological dependence develop with sustained use, and abrupt cessation carries seizure risksupported
BZD withdrawal: tremors, muscle spasticity, life-threatening seizures on abrupt cessation; review of mechanisms and management strategies. 0115680266296096240408032738
Among designer benzodiazepines, nifoxipam occupies the lowest potency tier — ranked alongside deschloroetizolam, metizolam, and pyrazolam — with an oral active dose range of 0.5–2 mg and an unusually protracted duration of action spanning 10–75 hours.partially supported
Nifoxipam ranked among least potent DBZDs. Potency score derived; structural analysis confirms ranking except nifoxipam anomalous. 0269881119901096
Claim in summary — inconclusiveinconclusiveworking →
The existing evidence base consists almost entirely of forensic toxicology case reports, analytical chemistry methods, and a single comprehensive review.supported
Review of chemistry, synthesis, pharmacology, toxicology, prevalence/use, biotransformation, and analysis. s11419-016-0338-5
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
No controlled toxicity data exist for nifoxipam in any species — no LD₅₀, no therapeutic index, and no lethal overdose attributed solely to this compound has been published. Respiratory depression constitutes the primary life-threatening risk, particularly in combination with other CNS depressantspartially supported
illicit BZDs combined with opiates lead to respiratory depression and death. dta.2211
pharmacokinetic-detail7 · 4 ok
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Manchester et al. measured the blood-to-plasma ratio of nifoxipam as part of a designer benzodiazepine panel; the specific value was reported in the full text but was not available from the abstract.supported
QSAR-modelled GABA-A receptor binding affinity and blood-to-plasma ratio data for designer BZDs including nifoxipam. s11419-022-00616-y
Nifoxipam is metabolized primarily through nitro-reduction (yielding 7-aminonifoxipam → 7-acetaminonifoxipam) and glucuronidationsupported
Nifoxipam extensively metabolized; main urinary target: 7-acetaminonifoxipam; also excreted as glucuronic acid conjugate of parent. s00216-016-9439-6
Class-level data suggest CYP3A4 involvement, but the compound's unusual UGT profile (requiring enzyme complexes rather than individual UGT1A4 activity) indicates that its metabolic pathway may diverge meaningfully from other designer benzodiazepines.supported
Glucuronide conjugates of nifoxipam only detected in pHLM, not attributable to individual UGTs, suggesting dimer complexes. Most DBZs glucuronidated by UGT1A4. dta.2463
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Primary urinary elimination products are 7-acetaminonifoxipam (most abundant), parent compound glucuronide, and unchanged parent compound.supported
main urinary target: 7-acetaminonifoxipam; also excreted as glucuronic acid conjugate of parent. s00216-016-9439-6
history6 · 3 ok
Claim in history — inconclusiveinconclusiveworking →
Flunitrazepam undergoes sequential N-demethylation and 3-hydroxylation in vivo to yield nifoxipam (3-hydroxy-N-desmethylflunitrazepam), an active metabolite that retains pharmacological activity at the GABA-A receptorsupported
Nifoxipam (3-hydroxy-desmethylflunitrazepam) are benzodiazepine derivatives and active metabolites of flunitrazepam. s11419-016-0338-5
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Moosmann et al. documented nifoxipam in 2015 as one of five newly available designer benzodiazepines sold online, alongside clonazolam, deschloroetizolam, flubromazolam, and meclonazepam.supported
Nifoxipam listed among 5 recently available designer BZDs in 2015. wps.20236
Trafficking was primarily confined to Europe during this initial period, with minimal data from the United States, Australia, or Japansupported
Seized in powder and tablet forms in Europe between 2014 and 2016. s11419-016-0338-5
receptor-pharmacology6 · 3 ok
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Its parent compound flunitrazepam is among the highest-affinity benzodiazepines at this site, but no direct measurement of nifoxipam's affinity has been published.supported
Flunitrazepam has greater potency and higher affinity for GABA-A receptor than most BZDs. jcph.1922
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Manchester et al. applied QSAR modelling to predict GABA-A receptor binding affinity for a panel of designer benzodiazepines including nifoxipam; the specific predicted value was not reported in the available abstract.supported
QSAR-modelled GABA-A receptor binding affinity and blood-to-plasma ratio data for designer BZDs including nifoxipam. s11419-022-00616-y
El Balkhi et al. classified nifoxipam in the lowest potency tier among 10 designer benzodiazepines analyzed, alongside deschloroetizolam, metizolam, and pyrazolamsupported
Analysis of 197 trip reports for 10 DBZDs including nifoxipam. Nifoxipam ranked among least potent DBZDs. 0269881119901096
neuroscience4 · 1 ok
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
What is nifoxipam's binding affinity at GABA-A receptor subtypes? Without Ki values, potency ranking relies entirely on subjective report analysis. Direct radioligand binding or fluorescence polarization assays could resolve the anomalous potency discrepancy identified by El Balkhi et al.supported
Nifoxipam ranked among least potent DBZDs. Potency score derived; structural analysis confirms ranking except nifoxipam anomalous. 0269881119901096
chemistry3 · 2 ok
The compound is the N-desmethyl-3-hydroxy derivative of flunitrazepam — differing from the parent by loss of the N-methyl group at position 1 and addition of a hydroxyl group at position 3.supported
Nifoxipam (3-hydroxy-desmethylflunitrazepam) are benzodiazepine derivatives and active metabolites of flunitrazepam. s11419-016-0338-5
The 3-hydroxyl group increases hydrophilicity relative to flunitrazepam, a modification that typically reduces blood-brain barrier penetration and may partially explain nifoxipam's lower observed potency.partially supported
structural analysis confirms ranking except nifoxipam anomalous. 0269881119901096
Claim in chemistry — inconclusiveinconclusiveworking →
clinical-evidence2 · 2 ok
STRIDA project (Sweden): Bäckberg et al. reported five analytically confirmed nifoxipam intoxication cases within the Swedish STRIDA toxicovigilance systemsupported
Nifoxipam detected in 5 of 217 NPS BZD intoxication cases in Sweden 2012-2016. 15563650.2018.1506130
All NPS benzodiazepine intoxication patients who were tested responded to flumazenil.supported
Flumazenil treatment effective. 15563650.2018.1506130
comparative-pharmacology2 · 2 ok
El Balkhi et al. analyzed user trip reports to rank the relative potency of 10 designer benzodiazepinessupported
Analysis of 197 trip reports for 10 DBZDs including nifoxipam. Potency score derived. 0269881119901096
Nifoxipam's position was anomalous — its observed potency was lower than structural features predicted.supported
structural analysis confirms ranking except nifoxipam anomalous. 0269881119901096